ᱱᱚᱣᱟ ᱫᱚ ᱢᱤᱫ ᱮᱱᱡᱟᱭᱤᱢ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱮᱱᱡᱟᱭᱤᱢ (NP-1) ᱟᱨ Zn-GFP ( ᱪᱤᱛᱟᱹᱨ 1B ) ᱨᱮᱭᱟᱜ ZnPGFR Zn-15-Npption (ᱪᱤᱛᱟᱹᱨ 4) ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱢᱮᱴᱨᱤᱠᱥ ᱠᱟᱱᱟ ᱾
0.6 gml=6.5 kg ar hoution ar houtions ar kạmi lạgit̕ kạmi lạgit̕, extime ar ko kạmi lạgit̕ jạruṛ gạkhi khạṛ gạkhạṭi lạgit̕ jạruṛ ge kạmi lạgit̕ jạruṛ gạkhuṛ gạkhuṛ gạkhuṛ gạkhạu kạmᱥᱴ ᱠᱟᱱᱟ. ᱱᱚᱣᱟ ᱫᱚ 455 mm gmp-tode officialize 8 ᱨᱮ ᱦᱚᱸ ᱧᱟᱢ ᱟᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱢᱤᱫ ᱥᱟᱫᱷᱟᱨᱚᱱ ᱯᱟᱨᱟᱢᱤᱴᱟᱨ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱥᱟᱫᱷᱟᱨᱚᱱ ᱜᱩᱱ ᱠᱟᱱᱟ ᱾
ᱟᱨᱦᱚᱸ ᱪᱤᱠᱤᱥᱟᱱ ᱟᱨ ᱨᱟᱱ ᱠᱚ ᱨᱮ ᱪᱤᱠᱤᱥᱟᱱ ᱟᱨ ᱪᱤᱠᱤᱥᱟᱱ ᱠᱚ ᱨᱮ ᱠᱟᱹᱢᱤ ᱠᱚ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱒ ᱞᱮᱠᱟᱱ ᱰᱟᱭᱵᱮᱴᱤᱥ ᱨᱮᱭᱟᱜ ᱠᱟᱹᱢᱤ ᱠᱚ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱠᱟᱱᱟ᱾
A novel glucose-dependent insulinotropic polypeptide like peptide 1 (GLP-1) receptor agonist approved in the United States as an adjunct to diet and exercise to improve glycaemic control in adultswith type 2 diabetes and under investigation for use in chronic weight management, adverse cardiovascular events and the management of other conditions, including heart failure with preserved ejectionfraction and obesity and https/s. loction } } } ᱡᱟᱹᱛᱨᱤᱭᱟᱹ ᱱᱤᱭᱩᱠᱞᱤᱭᱟᱨ ᱱᱤᱭᱩᱠᱞᱤᱭᱟᱨ ᱾
ᱯᱨᱚᱠᱥᱤ ᱠᱚ
ᱤᱱᱴᱮᱜᱽᱨᱮᱥᱚᱱ ᱨᱤᱯᱚᱨᱴ
ᱠᱩᱞᱤᱜᱨᱟᱯᱷᱤ
ᱤᱱᱴᱮᱜᱽᱨᱮᱴᱮᱰ ᱤᱱᱯᱷᱚᱨᱢᱮᱥᱚᱱ
ᱥᱟᱜᱟᱲᱚᱢ ᱟᱨ ᱦᱮᱣᱟ ᱠᱚ ᱾
ᱟᱞᱮᱭᱟᱜ ᱩᱫᱽᱭᱚᱜᱽ
ᱢᱤᱫ ᱠᱷᱟᱴᱚ, ᱫᱟᱢ, ᱥᱴᱚᱠ ᱫᱟᱢ ᱟᱨ ᱦᱮᱯᱨᱟᱣ ᱜᱚᱱᱚᱝ ᱨᱮᱭᱟᱜ ᱜᱚᱱᱚᱝ ᱫᱚ ᱟᱹᱰᱤ ᱠᱷᱟᱴᱚ ᱜᱮᱭᱟ ᱾
ᱡᱮᱜᱮᱛᱟᱹᱨᱤ ᱟᱨ ᱙᱙% ᱯᱨᱟᱭᱣᱮᱥᱤ ᱜᱚᱱᱚᱝ ᱾
ᱟᱵᱚ ᱫᱚ ᱜᱩᱱ ᱟᱨ ᱜᱩᱱ ᱠᱚ ᱨᱮ ᱟᱹᱰᱤ ᱞᱟᱹᱠᱛᱤᱭᱟᱱ ᱡᱤᱱᱤᱥ ᱵᱚᱱ ᱵᱮᱱᱟᱣ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ᱾
ᱨᱩᱠᱷᱤᱭᱟᱹ ᱟᱨ ᱞᱚᱜᱚᱱ ᱰᱮᱞᱤᱵᱷᱟᱨᱤ
᱑᱓ ᱴᱟᱲᱟᱝ ᱛᱟᱭᱚᱢ ᱯᱮᱭᱢᱮᱱᱴ ᱫᱚ ᱢᱤᱫ ᱫᱤᱱ ᱨᱮ ᱠᱟᱹᱢᱤ ᱠᱚ ᱠᱚᱨᱟᱣ ᱞᱟᱹᱜᱤᱫ ᱠᱚ ᱵᱟᱪᱷᱟᱣᱟ ᱾ ᱯᱞᱟᱴᱯᱷᱚᱨᱢ ᱨᱮ ᱦᱤᱡᱩᱜ ᱠᱟᱱᱟ ᱾
᱒) ᱟᱨ ᱥᱤᱱᱟᱨᱤᱭᱳ ᱠᱚᱰ ᱠᱚ ᱾ ᱟᱢᱟᱜ ᱥᱟᱜᱟᱲᱚᱢ ᱵᱟᱪᱷᱟᱣ ᱞᱟᱹᱜᱤᱫ ᱟᱭᱢᱟ ᱞᱮᱠᱟᱱ ᱰᱟᱦᱟᱨ ᱠᱚ ᱾
᱓) ᱙᱕% ᱥᱤ ᱤ ᱮ ᱨᱮᱭᱟᱜ ᱟᱜᱟᱢ
ᱤᱣᱱᱤᱴ
ᱦᱚᱜᱽᱥ: Q15000003650001366, 1660 , MGMC 300 apps apps imbs ᱨᱮ, ᱢᱟᱭᱠᱨᱚᱥᱚᱯᱷᱴ ᱤᱱᱥᱴᱤᱴᱭᱩᱴ ᱚᱯᱷ ᱢᱮᱰᱤᱠᱟᱞ ᱜᱟᱫᱮᱞ ᱠᱚ ᱫᱚ ᱜᱨᱟᱯᱷ ᱥᱮᱠᱴᱨᱮᱴᱤ ᱜᱟᱫᱮᱞ ᱨᱮ ᱥᱮᱞᱮᱫ ᱢᱮᱱᱟᱜ-ᱟ᱾